Idaho Is Getting Purdue Pharma Settlement Money , The State’s Opioid Crisis Is Not Over

Witnessing a sizable legal settlement land in a state that has been quietly bleeding from a situation the settlement was meant to address evokes a certain emotion. From the finalized $7.4 billion countrywide deal with Purdue Pharma and the Sackler family, Idaho will get about $24.4 million. Over the course of 15 years, the majority of the funds will arrive in the first three.

The arrangement has been appropriately portrayed by Attorney General Raúl Labrador as the culmination of years of litigation and as part of the state’s larger recovery of $127 million connected to opioids since January 2023. The figures are accurate. There is actual accountability. But in ways that the Purdue settlement was never intended to address, the situation those figures are supposed to address has continued to change.

You can learn something about how Idaho plans to use the funds from the distribution structure. For behavioral health services, the state receives 40%. Counties and cities receive 40% of the flow. Public health districts receive twenty percent. Over the previous ten years, the state policy community has learned something that is reflected in the split. At the state capital level, opioid response cannot be fully controlled. In locations like Boise, Coeur d’Alene,

Twin Falls, and the tiny rural towns where the epidemic frequently causes the most concentrated harm, treatment, prevention, and overdose response are actually provided at the county and district levels. The appropriateness of front-loading the monies across these three layers will be evident to anyone who has worked with Idaho’s addiction programs. There is an urgent need. Only until funding reaches the operational levels where the work actually takes place does the administrative system to absorb the money exist, although imperfectly.

However, the crisis’s actual form has changed more quickly than the settlement structure predicted. OxyContin, the prescription medication whose aggressive marketing in the late 1990s and early 2000s is sometimes cited as a primary cause of the wider opioid catastrophe, served as the foundation for Purdue Pharma’s involvement in the opioid epidemic. That chapter was completed in 2020 with the filing for bankruptcy and the following guilty plea to federal criminal charges pertaining to the marketing of OxyContin.

Selling narcotics in the US is now permanently prohibited for the Sackler family. The private firm Purdue Pharma is being dissolved. By historical standards, the legal responsibility is exceptionally clean. The issue is that OxyContin is no longer the primary source of the deaths driving Idaho’s current opioid mortality statistics. They are brought on by fentanyl, a synthetic opioid that has proliferated in the nation’s illegal drug markets and has little to do with the prescription drug market that the Purdue deal addressed.

This disparity is painfully evident in the Idaho mortality numbers. The state recorded 386 overdose deaths overall and 265 opioid-related deaths in 2023, the highest number since the state started routinely gathering data. 38% of overdose deaths in 2024 were caused by fentanyl, and data from early 2026 indicates that synthetic opioid deaths are still a public health issue even if some areas are witnessing slight declines.

Although there is some solace in the fact that Idaho’s per-capita rates are still lower than the national average, the problem’s trajectory has not obviously changed for the better. The problem facing the state agencies and local health districts who are currently receiving Purdue monies is that the money is coming to deal with a crisis whose main cause has essentially moved on from the issues the settlement was intended to solve.

The cultural context merits consideration. One of the most well-researched and recorded public health emergencies in American history is the opioid crisis. Books like Patrick Radden Keefe’s Empire of Pain and Beth Macy’s Dopesick have helped the public comprehend the Sackler family’s participation in a way that would have been nearly unthinkable ten years ago. This settlement’s legal accountability was, in many respects, the result of years of federal inquiry, plaintiff bar mobilization, and state attorney general collaboration.

Anyone who has followed the litigation through the legal system since the mid-2010s is aware of how many court battles were necessary to get this result. Even if the Sackler family’s fortune is still mostly intact, the fact that they are now permanently prohibited from selling opioids in the US is a significant piece of legal history.

Even while the $24 million cannot match the scope of the ongoing epidemic, it is important because of the broader financial situation for opioid response. Like most state systems, Idaho’s behavioral health system has long been underfunded in comparison to its needs. There are not enough treatment beds. There are few urban facilities that offer detox services. Medication-assisted treatment, an evidence-based strategy that uses methadone or buprenorphine to stabilize individuals in recovery, is frequently inaccessible in rural areas.

None of these systemic issues can be resolved by Purdue cash alone. If used wisely, they can support pilot projects, increase current capacity, and establish local treatment infrastructure that can subsequently be maintained with additional funding sources. Idaho officials must decide whether to concentrate the funding on a small number of interventions where it could result in quantifiable impact or to distribute it widely among numerous programs.